Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


England Launches Innovative Medicines Fund

Executive Summary

The new financing mechanism promises faster access to new treatments, but some industry concerns remain unresolved.

You may also be interested in...

England’s Unused Innovative Medicines Fund Under Fire Again

A group of UK academics have broadly welcomed the fund that will pay for innovative non-cancer drugs, but have expressed concern over issues such as the entry criteria and the definition of “high unmet need.” They also say safeguards are needed against possible financial loss to the National Health Service.

England’s Innovative Medicines Fund: Opportunities & Risks

England’s Innovative Medicines Fund could make the UK a more attractive launch market following Brexit, but companies must also consider the risks of the fund.

England: HTA Body NICE Makes Big RWE Push

England’s health technology appraisal institute, NICE, has published its real-world evidence framework.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts